Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESPR Esperion Therapeutics

Trading 05-13 14:18:44 EDT

3.13

+0.00

-0.16%

High3.14	Low3.12	Vol8.18M
Open3.13	D1 Closing3.13	Amplitude0.64%
Mkt Cap802.53M	Tradable Cap740.63M	Total Shares256.81M
T/O25.60M	T/O Rate3.45%	Tradable Shares237.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics","latestPrice":3.125,"timestamp":1778696322391,"preClose":3.13,"halted":0,"volume":8182090,"delay":0,"changeRate":-0.0015974440894568351,"floatShares":237000000,"shares":256810500,"eps":-0.033486,"marketStatus":"Trading","change":-0.005,"latestTime":"05-13 14:18:44 EDT","open":3.13,"high":3.14,"low":3.12,"amount":25604751.800313,"amplitude":0.00639,"askPrice":3.13,"askSize":458027,"bidPrice":3.12,"bidSize":648712,"shortable":3,"etf":0,"ttmEps":-0.033486,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778702400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":3.13,"preHourTrading":{"tag":"盘前","latestPrice":3.13,"preClose":3.13,"latestTime":"09:29 EDT","volume":11316,"amount":35433.9413028,"timestamp":1778678999918,"change":0,"changeRate":0,"amplitude":0.01278},"postHourTrading":{"tag":"盘后","latestPrice":3.13,"preClose":3.13,"latestTime":"18:09 EDT","volume":147859,"amount":462798.67,"timestamp":1778623762301,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.689701,"impliedVol":0.1703,"impliedVolPercentile":0.0438},"requestUrl":"/m/hq/s/ESPR/tweets","defaultTab":"tweets","newsList":[{"id":"2635632784","title":"Esperion reports Phase 2 pediatric study shows bempedoic acid lowers LDL-C in HeFH","url":"https://stock-news.laohu8.com/highlight/detail?id=2635632784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635632784?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:03","pubTimestamp":1778673808,"startTime":"0","endTime":"0","summary":"Esperion flagged new analyses on bempedoic acid, with results scheduled for presentation May 24-27 at European Atherosclerosis Society Congress 2026 in Athens.Separate analysis from CLEAR Outcomes identified patient characteristics linked to more pronounced LDL-C lowering in statin-intolerant adults, aiming to guide use in clinical practice.Company also slated encore presentations from CLEAR Outcomes analyses on venous thromboembolism risk, stroke incidence, and outcomes without background lipid-lowering therapy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL1s866n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD","BK4585","ESPR","LU2095319765.USD","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4007","IE00BN0W2V16.EUR","LU0314104364.USD","BK4588","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635082782","title":"Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635082782","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635082782?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673600,"startTime":"0","endTime":"0","summary":"–Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293947/0/en/Esperion-Announces-Two-New-Analyses-Supporting-Bempedoic-Acid-to-Reduce-LDL-C-Levels-to-be-Presented-at-the-European-Atherosclerosis-Society-EAS-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR","LDL","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635892242","title":"Analysts’ Top Healthcare Picks: Passage Bio (PASG), Esperion (ESPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635892242","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635892242?lang=en_us&edition=fundamental","pubTime":"2026-05-13 03:10","pubTimestamp":1778613006,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Passage Bio (PASG) and Esperion (ESPR) with neutral ratings, indicating that the experts are neither ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-passage-bio-pasg-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-passage-bio-pasg-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","LU0128526141.USD","XLV","LU0029874061.USD","PASG","BK4585","ESPR","BK4007","BK4137","HCSG","BK4581","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634449670","title":"Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2634449670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634449670?lang=en_us&edition=fundamental","pubTime":"2026-05-10 14:02","pubTimestamp":1778392935,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (ESPR) has disclosed a new risk, in the Regulation category. The discussion emphasizes that Esperion Therapeutics’ Form 10-Q ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/esperion-therapeutics-10-q-forward-looking-statements-highlight-significant-uncertainty-and-investor-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/esperion-therapeutics-10-q-forward-looking-statements-highlight-significant-uncertainty-and-investor-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634458734","title":"Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2634458734","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634458734?lang=en_us&edition=fundamental","pubTime":"2026-05-10 10:42","pubTimestamp":1778380977,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (ESPR) closed out FY 2025 with fourth quarter revenue of US$168.4 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$403.1 million and a basic EPS loss of US$0.11. Over recent quarters the company has seen revenue move from US$69.1 million in Q4 2024 to US$168.4 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 in Q4 2024 to EPS of US$0.26 in Q4 2025. This sets up a results season in which investors will be weighing how...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-espr/esperion-therapeutics/news/esperion-therapeutics-espr-q4-profit-swing-challenges-bearis","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-espr/esperion-therapeutics/news/esperion-therapeutics-espr-q4-profit-swing-challenges-bearis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634490362","title":"EXE, IP, ESPR, CMPS, TNXP Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2634490362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634490362?lang=en_us&edition=fundamental","pubTime":"2026-05-09 17:00","pubTimestamp":1778317257,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($EXE) ), ( ($IP) ), ( ($ESPR) ), ( ($CMPS) ) and ( ($TNXP) ). Here is a breakdown of their recent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/exe-ip-espr-cmps-tnxp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/exe-ip-espr-cmps-tnxp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS","IE00B3T34201.USD","LU1169590202.USD","BK4136","ESPR","LU2543165471.USD","IP","LU1481600234.SGD","BK4585","BK4583","LU1481599808.USD","BK4007","BK4588","LU1804176565.USD","LU1487256676.USD","EXE","BK4139","BK4213","LU1169589451.USD","TNXP","LU2265009873.SGD","LU2463526074.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634920467","title":"Esperion Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634920467","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634920467?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:11","pubTimestamp":1778274665,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryEsperion Therapeutics Inc ESPR.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634280464","title":"Esperion Q1 net loss narrows to $25.2 million; product sales rise to $43.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634280464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634280464?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:15","pubTimestamp":1778271306,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics posted a net loss of USD 25.2 million, narrowing from USD 40.5 million a year earlier.Net sales rose 24.3% to USD 43.4 million, supported by prescription growth volumes of NEXLETOL and NEXLIZET.Loss from operations narrowed to USD 6.6 million, while research and development expense fell to USD 9 million.Collaboration revenue increased to USD 36.7 million on higher royalty sales growth in partner territories, while interest expense edged up to USD 19.8 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL7HQ2vw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633992044","title":"U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi","url":"https://stock-news.laohu8.com/highlight/detail?id=2633992044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633992044?lang=en_us&edition=fundamental","pubTime":"2026-05-05 15:07","pubTimestamp":1777964820,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, OnsemiMay 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL4N41I0F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GBTG","DT","CVX","PLTR","ICHR","AXSM","APD","NCLH","CNO","CORD","ESPR","PLOO","PLTW","CLYM","GPI","EVER","MZTI","COIN","CRWV","CHD","H","ICOI","AMAT","CONX","CRWG","KNSL","PLTU","DUOL","TGT","DOGD","ARE","RBLX","COIW","FLGT","PINS","LRCX","LSCC","BR","CBRE","HUBB","DDOG","RBA","WGS","RYAN","INSP","CRCL","PLTY","AEIS","ACMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633992848","title":"BRIEF-BioPharma Credit Says Co's Allocation Of Financing Of Esperion Deal  Between $78 Million And $120 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633992848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633992848?lang=en_us&edition=fundamental","pubTime":"2026-05-05 14:37","pubTimestamp":1777963063,"startTime":"0","endTime":"0","summary":"BRIEF-BioPharma Credit Says Co's Allocation Of Financing Of Esperion Deal  Between $78 Million And $120 MillionMay 5 (Reuters) - BioPharma Credit PLC BPCR.L:BIOPHARMA CREDIT PLC  - STATEMENT RE ARCHIM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUCV2BMQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BPCR.UK","ESPR","BK5078"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633994306","title":"Biopharma Credit Plc - Co's Allocation of Financing of Esperion Deal  Between $78 Mln and $120 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633994306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633994306?lang=en_us&edition=fundamental","pubTime":"2026-05-05 14:00","pubTimestamp":1777960813,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUCV2BMQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK5078","BK4007","ESPR","BPCR.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633699543","title":"Esperion Therapeutics Inc : Needham Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2633699543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633699543?lang=en_us&edition=fundamental","pubTime":"2026-05-05 11:39","pubTimestamp":1777952396,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nFWN41H0TR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633968607","title":"Esperion Therapeutics Cut to Hold From Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2633968607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633968607?lang=en_us&edition=fundamental","pubTime":"2026-05-05 03:15","pubTimestamp":1777922100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 15:15 ET (19:15 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633968429","title":"Esperion downgraded to Hold from Buy at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2633968429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633968429?lang=en_us&edition=fundamental","pubTime":"2026-05-05 03:10","pubTimestamp":1777921814,"startTime":"0","endTime":"0","summary":"Needham downgraded Esperion (ESPR) to Hold from Buy after the company announced it will be acquired by Archimed for $3.16 per share and a $100M con...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-downgraded-to-hold-from-buy-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-downgraded-to-hold-from-buy-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633968447","title":"Esperion (ESPR) was downgraded to a Hold Rating at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2633968447","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633968447?lang=en_us&edition=fundamental","pubTime":"2026-05-05 03:05","pubTimestamp":1777921535,"startTime":"0","endTime":"0","summary":"Esperion received a Hold rating and price target from Needham analyst Serge Belanger today. According to TipRanks, Belanger is a 5-star analyst wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/esperion-espr-was-downgraded-to-a-hold-rating-at-needham-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/esperion-espr-was-downgraded-to-a-hold-rating-at-needham-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632193038","title":"Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2632193038","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632193038?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:21","pubTimestamp":1777893707,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics (ESPR) has an average rating of hold and mean price target of $3.55, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647881","title":"Esperion Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647881","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647881?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:08","pubTimestamp":1777666080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2026 16:08 ET (20:08 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642598","title":"Esperion downgraded to Hold from Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642598","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642598?lang=en_us&edition=fundamental","pubTime":"2026-05-02 03:26","pubTimestamp":1777663563,"startTime":"0","endTime":"0","summary":"Jefferies downgraded Esperion (ESPR) to Hold from Buy with a price target of $3.28, down from $5, after the company announced it will be acquired b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-downgraded-to-hold-from-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-downgraded-to-hold-from-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632416136","title":"Esperion downgraded to Neutral from Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2632416136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632416136?lang=en_us&edition=fundamental","pubTime":"2026-05-02 02:06","pubTimestamp":1777658810,"startTime":"0","endTime":"0","summary":"Piper Sandler downgraded Esperion (ESPR) to Neutral from Overweight with a price target of $3.16, down from $9, after funds managed by Archimed ann...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-downgraded-to-neutral-from-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-downgraded-to-neutral-from-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632649491","title":"BUZZ-U.S. STOCKS ON THE MOVE-Perella Weinberg Partners, Amkor Technology, Esperion Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2632649491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632649491?lang=en_us&edition=fundamental","pubTime":"2026-05-02 01:51","pubTimestamp":1777657903,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Perella Weinberg Partners, Amkor Technology, Esperion Therapeutics  Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3L","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL6N41E0E9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWP","SDOT","AAPX","CL","PSKY","VEEV","EL","ZETA","TWLO","NWL","ARVN","AAPB","SST","AAPD","BIO","SENS","CREG","WDAY","AMGN","CHD","MRNA","RIVN","DDOG","XOMO","XOMZ","AAPL","CRM","AMKR","RBLX","TEAM","CTRA","RVNL","WNC","RYTM","SOBR","CRMG","CLX","NOW","AAPW","RMD","AAPU","ESPR","INTU","RDDT","CUE","CVX","HUBC","XOM","PFE","ATMU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":0.0032},{"period":"1month","weight":0.4424},{"period":"3month","weight":-0.0954},{"period":"6month","weight":0.0574},{"period":"1year","weight":2.9179},{"period":"ytd","weight":-0.1541}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.043403},{"month":2,"riseRate":0.461538,"avgChangeRate":0.113863},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.039729},{"month":4,"riseRate":0.384615,"avgChangeRate":-0.046726},{"month":5,"riseRate":0.692308,"avgChangeRate":0.013472},{"month":6,"riseRate":0.75,"avgChangeRate":0.035061},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Esperion Therapeutics,ESPR,Esperion Therapeutics股票,Esperion Therapeutics股票老虎,Esperion Therapeutics股票老虎国际,Esperion Therapeutics行情,Esperion Therapeutics股票行情,Esperion Therapeutics股价,Esperion Therapeutics股市,Esperion Therapeutics股票价格,Esperion Therapeutics股票交易,Esperion Therapeutics股票购买,Esperion Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction